<DOC>
	<DOCNO>NCT02450058</DOCNO>
	<brief_summary>In multicenter , randomize phase III trial , node positive early breast cancer patient randomly assign receive either 6 cycle FEC ( 5-fluorouracil 600 mg/m2 , epirubicin 60 mg/m2 cyclophosphamide 600 mg/m2 , day 1 , every three week ) 4 cycle EP ( epirubicin 90 mg/m2 paclitaxel 175 mg/m2 , day 1 , every three week ) . The primary study endpoint overall survival ( OS ) . Secondary endpoint include toxicity event free survival ( EFS ) .</brief_summary>
	<brief_title>Adjuvant FEC Versus EP Breast Cancer ( MIG5 )</brief_title>
	<detailed_description>At time Gruppo Oncologico Nord-Ovest- Mammella Intergruppo trial 5 ( GONO-MIG5 ) design 1996 , paclitaxel know efficacy patient advance breast cancer , role still establish adjuvant setting . Therefore GONO-MIG5 trial design compare standard anthracycline-containing chemotherapy regimen , i.e . 5fluorouracil , epirubicin , ciclophosphamide ( FEC ) , give 6 cycle new regimen contain epirubicin paclitaxel ( EP ) , give concurrently , 4 cycle . This latter regimen choose basis result obtain metastatic breast cancer patient , combination doxorubicin paclitaxel associate 90 % objective response . Only four cycle new regimen plan since expect toxicity , particularly cardiotoxicity , high , short treatment duration hop best strategy obtain favourable balance toxicity expect high efficacy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Women histologically confirm breast cancer undergone radical mastectomy breastconserving surgery addition full ipsilateral axillary lymph node dissection Lymph nodepositive disease le 10 involved axillary lymph node Surgery perform 5 week randomization ECOG performance status 0 Absolute neutrophil count ≥ 2,000/mm³ WBC ≥ 3,000/mm³ Platelet count ≥ 100,000/mm³ Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 1.5 time ULN Postoperative regional radiotherapy limit remain breast admit patient receive breastconserving surgery Written inform consent Prior concurrent ipsilateral contralateral invasive breast carcinoma within last 10 year Metastatic disease , include metastasis ipsilateral supraclavicular lymph node Prior chemotherapy prior cytotoxic regimen prior hormonal therapy Pregnant nursing Other serious medical illness require medication , uncontrolled infection Other malignancy except adequately treat , conebiopsied situ carcinoma cervix basal cell squamous cell carcinoma skin Recent myocardial infarction , congestive heart failure , serious arrhythmia</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>early breast cancer</keyword>
	<keyword>adjuvant chemotherapy</keyword>
	<keyword>FEC</keyword>
	<keyword>paclitaxel</keyword>
</DOC>